{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T18:26:16Z","timestamp":1748370376990},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>When, whether, and in whom primary tumor resection (PTR) for patients with metastatic colorectal cancer (CRC) is indicated remains unknown. With advances in multiagent systemic chemotherapy, PTR may be undertaken less frequently. The aim of this study was to obtain estimates of changes in the utilization of PTR and chemotherapy for metastatic CRC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Patients diagnosed with metastatic CRC between 2000 and 2016 were identified from Surveillance Epidemiology, and End Results (SEER) registry. Multivariable logistic regression defined odds of undergoing PTR. The analysis was also stratified by primary site (colon vs. rectum), age (younger than 50 vs. 50\u2009y and older), and whether patients also underwent resection of metastatic sites (yes vs. no). The secondary endpoint of interest was the receipt of any chemotherapy, also assessed by multivariable logistic regression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Among 99,835 patients with metastatic CRC, 55,527 (55.7%) underwent PTR. The odds of undergoing PTR decreased with a later year of diagnosis, with patients diagnosed in 2016 being 61.1% less likely to undergo surgery than those diagnosed in 2000 (adjusted odds ratio=0.39, 95% confidence interval: 0.36-0.42, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001; absolute percentage: 62.3% to 43.8%). Similar trends by year for PTR were observed among each of the subgroups, although patients with colon primary, young adults (age younger than 50\u2009y), and patients also undergoing metastasectomy were more likely to undergo PTR (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001 for all). In contrast, the odds of receiving chemotherapy increased dramatically with a later year of diagnosis (adjusted odds ratio=2.21, 95% confidence interval: 2.04-2.40, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>From 2000 to 2016, there was a sharp decline in the rate of PTR for patients with metastatic CRC, while the use of chemotherapy increased over the same period. Prospective studies are needed to define the optimal local treatment for patients with metastatic CRC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000764","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T15:03:10Z","timestamp":1601046190000},"page":"850-856","source":"Crossref","is-referenced-by-count":5,"title":["Trends in Primary Surgical Resection and Chemotherapy for Metastatic Colorectal Cancer, 2000-2016"],"prefix":"10.1097","volume":"43","author":[{"given":"Nina N.","family":"Sanford","sequence":"first","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Folkert","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd A.","family":"Aguilera","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad S.","family":"Beg","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed A.","family":"Kazmi","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aravind","family":"Sanjeevaiah","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert J.","family":"Zeh","sequence":"additional","affiliation":[{"name":"Surgery, University of Texas Southwestern, Dallas, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Farkas","sequence":"additional","affiliation":[{"name":"Surgery, University of Texas Southwestern, Dallas, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1053\/ejso.2001.1120","article-title":"Survival and quality of life after palliative surgery for neoplastic gastrointestinal obstruction","volume":"27","author":"Legendre","year":"2001","journal-title":"Eur J Surg Oncol"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/BF02051920","article-title":"Palliative operations for colorectal cancer","volume":"33","author":"Makela","year":"1990","journal-title":"Dis Colon Rectum"},{"issue":"suppl 4","key":"R7-20230903","doi-asserted-by":"crossref","first-page":"Abstract 7","DOI":"10.1200\/JCO.2020.38.4_suppl.7","article-title":"A randomized phase III trial comparing primary tumor resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 study (iPACS)","volume":"38","author":"Kanemitsu","year":"2020","journal-title":"J Clin Oncol"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"djw322","DOI":"10.1093\/jnci\/djw322","article-title":"Colorectal cancer incidence patterns in the United States, 1974-2013","volume":"109","author":"Siegel","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamasurg.2014.1756","article-title":"Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010","volume":"150","author":"Bailey","year":"2015","journal-title":"JAMA Surg"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/modpathol.2012.61","article-title":"Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features","volume":"25","author":"Chang","year":"2012","journal-title":"Mod Pathol"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.cgh.2010.10.021","article-title":"Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer","volume":"9","author":"Limburg","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1002\/cncr.31994","article-title":"Clinical and molecular characterization of early-onset colorectal cancer","volume":"125","author":"Willauer","year":"2019","journal-title":"Cancer"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","volume":"345","author":"Flanigan","year":"2001","journal-title":"N Engl J Med"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","article-title":"Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial","volume":"358","author":"Mickisch","year":"2001","journal-title":"Lancet"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/SLA.0000000000000860","article-title":"Prognostic relevance of palliative primary tumor removal in 37,793 metastatic colorectal cancer patients: a population-based, propensity score-adjusted trend analysis","volume":"262","author":"Tarantino","year":"2015","journal-title":"Ann Surg"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrclinonc.2014.96","article-title":"The oligometastatic state\u2014separating truth from wishful thinking","volume":"11","author":"Palma","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.2008.19.6386","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for lung metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/jamasurg.2013.1431","article-title":"Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases","volume":"148","author":"Karanicolas","year":"2013","journal-title":"JAMA Surg"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1148\/radiol.2015142489","article-title":"Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes\u2014a 10-year experience at a single center","volume":"278","author":"Shady","year":"2016","journal-title":"Radiology"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"R27-20230903","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"R28-20230903","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"key":"R29-20230903","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41416-019-0526-2","article-title":"Exploring the best treatment options for BRAF-mutant metastatic colon cancer","volume":"121","author":"Taieb","year":"2019","journal-title":"Br J Cancer"},{"key":"R30-20230903","doi-asserted-by":"crossref","first-page":"411","DOI":"10.6004\/jnccn.2017.0038","article-title":"Right versus left colon cancer biology: integrating the consensus molecular subtypes","volume":"15","author":"Lee","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"R31-20230903","doi-asserted-by":"crossref","first-page":"6576","DOI":"10.1200\/JCO.2005.06.102","article-title":"Patients\u2019 perceptions of quality of care for colorectal cancer by race, ethnicity, and language","volume":"23","author":"Ayanian","year":"2005","journal-title":"J Clin Oncol"},{"key":"R32-20230903","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/cncr.10645","article-title":"Socioeconomic and demographic disparities in treatment for carcinomas of the colon and rectum","volume":"95","author":"VanEenwyk","year":"2002","journal-title":"Cancer"},{"key":"R33-20230903","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1200\/JCO.2015.65.0994","article-title":"Racial\/ethnic disparities in survival among patients with young-onset colorectal cancer","volume":"34","author":"Holowatyj","year":"2016","journal-title":"J Clin Oncol"},{"key":"R34-20230903","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1053\/j.gastro.2018.11.060","article-title":"Racial disparities in incidence of young-onset colorectal cancer and patient survival","volume":"156","author":"Murphy","year":"2019","journal-title":"Gastroenterology"},{"key":"R35-20230903","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/jamasurg.2014.3572","article-title":"Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains","volume":"150","author":"Kneuertz","year":"2015","journal-title":"JAMA Surg"},{"key":"R36-20230903","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jamasurg.2016.5050","article-title":"Chemotherapy use and survival among young and middle-aged patients with colon cancer","volume":"152","author":"Manjelievskaia","year":"2017","journal-title":"JAMA Surg"},{"key":"R37-20230903","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.18.01074","article-title":"Comparison of population-based observational studies with randomized trials in oncology","volume":"37","author":"Soni","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T04:08:58Z","timestamp":1693714138000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000764","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,23]]}}}